Drug Trial Radar · NCT05696080
Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)
Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
518
Actual
Start
Feb 13, 2023
Primary completion
Feb 16, 2024
Study completion Feb 16, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to evaluate the safety and tolerability of the pneumococcal 21 valent conjugate vaccine (V116), and to evaluate the serotype-specific opsonophagocytic activity (OPA) post-vaccination with V116 and PCV15 (a pneumococcal conjugate vaccine that includes 15 serotypes) + PPSV23 (comprised of the polysaccharides from 23 of the serotypes causing disease in adults) post-vaccination within each vaccination group separately.
Conditions
- Pneumococcal Infection
Interventions
V116Biological
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
PlaceboBiological
Saline in each 0.5 mL sterile solution
PCV15Biological
Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
PPSV23Biological
Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Solicited Injection-site Adverse Events (AEs) From Day 1 Through Day 5 Post-vaccinationTime frame: Up to 5 days following each vaccination
- Participants With Solicited Systemic AEs From Day 1 Through Day 5 Post-vaccinationTime frame: Up to 5 days following each vaccination
- Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through The Duration of Participation in The StudyTime frame: Up to 194 days following Visit 2 (Day 1)
- Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Pneumococcal Serotypes Contained in V116Time frame: 30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group.
Locations
44 sites in 8 countries. Site status is shown where the registry gives one.
Aventiv Research ( Site 0022)
Mesa, Arizona
Indago Research & Health Center, Inc ( Site 0002)
Hialeah, Florida
Triple O Research Institute, P.A ( Site 0011)
West Palm Beach, Florida
SKY Integrative Medical Center/SKYCRNG ( Site 0012)
Ridgeland, Mississippi
Mid Hudson Medical Research ( Site 0008)
New Windsor, New York
Holston Medical Group ( Site 0010)
Kingsport, Tennessee
EmVenio Research ( Site 0018)
Fort Worth, Texas
Wenatchee Valley Hospital ( Site 0019)
Wenatchee, Washington
Holdsworth House Medical Practice ( Site 0402)
Darlinghurst, New South Wales, Australia
Royal Brisbane and Women's Hospital ( Site 0400)
Brisbane, Queensland, Australia
G A Research Associates ( Site 0100)
Moncton, New Brunswick, Canada
Hamilton Medical Research Group ( Site 0107)
Hamilton, Ontario, Canada
Milestone Research Inc. ( Site 0106)
London, Ontario, Canada
Manna Research Mirabel ( Site 0105)
Mirabel, Quebec, Canada
Clinique de médecine Urbaine du Quartier Latin ( Site 0111)
Montreal, Quebec, Canada
Diex Recherche Trois-Rivieres ( Site 0110)
Trois-Rivières, Quebec, Canada
Diex Recherche Victoriavile Inc. ( Site 0102)
Victoriaville, Quebec, Canada
Hospital Dr. Hernán Henríquez Aravena ( Site 1001)
Temuco, Araucania, Chile
Centro de Investigación del Maule-Centro de Investigación 2 ( Site 1010)
Talca, Maule Region, Chile
Universidad San Sebastian - Providencia ( Site 1003)
Providencia, Region M. de Santiago, Chile
Centro de Investigaciones Medicas Respiratorias (CIMER) ( Site 1008)
Santiago, Region M. de Santiago, Chile
Centro de Investigacion Clinicadela Universidad Catolica ( Site 1004)
Santiago, Region M. de Santiago, Chile
Universidad de Chile - Hospital Clínico Universidad de Chile-Cardiology ( Site 1006)
Santiago, Region M. de Santiago, Chile
CESFAM Esmeralda ( Site 1009)
Santiago, Region M. de Santiago, Chile
Medical corporation Applied Bio-Pharmatech Kurume Clinical Pharmacology Clinic ( Site 0200)
Kurume, Fukuoka, Japan
Shimonoseki Medical Center ( Site 0201)
Shimonoseki, Yamaguchi, Japan
P3 Research - Wellington ( Site 0503)
Wellington, New Zealand
Pacific Clinical Research Network - Rotorua ( Site 0500)
Rotorua, Bay of Plenty, New Zealand
P3 Research - Tauranga ( Site 0507)
Tauranga, Bay of Plenty, New Zealand
CGM Research Trust ( Site 0505)
Christchurch, Canterbury, New Zealand
Pacific Clinical Research Network - Forte ( Site 0501)
Christchurch, Canterbury, New Zealand
P3 Research - Lower Hutt ( Site 0508)
Lower Hutt, Wellington Region, New Zealand
IN VIVO ( Site 0601)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Centrum Medyczne Pratia Bydgoszcz-Centrum Medyczne Pratia Bydgoszcz ( Site 0607)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
MICS Centrum Medyczne Torun ( Site 0606)
Torun, Kuyavian-Pomeranian Voivodeship, Poland
Clinmedica Research Sp. z. o. o. ( Site 0603)
Skierniewice, Łódź Voivodeship, Poland
Centrum Medyczne Medyk ( Site 0602)
Rzeszów, Podkarpackie Voivodeship, Poland
Centrum Medyczne Pratia Katowice ( Site 0604)
Katowice, Silesian Voivodeship, Poland
Clinical Medical Research ( Site 0605)
Katowice, Silesian Voivodeship, Poland
Korea University Anam Hospital ( Site 0305)
Seoul, South Korea
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.